Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function

por Borin, Marie T, Lo, Arthur, Barnes, Chris N, Pendyala, Srikanth, Bourdet, David L
Publicado 2019

A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease

por Pudi, Krishna K., Barnes, Chris N., Moran, Edmund J., Haumann, Brett, Kerwin, Edward
Publicado 2017

Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III tri...

por Sethi, Sanjay, Donohue, James F., Ferguson, Gary T., Barnes, Chris N., Crater, Glenn D.
Publicado 2020

Telavancin in Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP) Caused by Staphylococcus aureus: Post Hoc Analysis of 2 Randomized, Controlled Trials

por Niederman, Michael S., Lee, Patrick C., Barriere, Steven L., Barnes, Chris N., Castaneda-Ruiz, Bibiana
Publicado 2019

Revefenacin, a Long‐Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo‐ and Positive‐Controlled Thorough QT Study

por Borin, Marie T., Barnes, Chris N., Darpo, Borje, Pendyala, Srikanth, Xue, Hongqi, Bourdet, David L.
Publicado 2019

Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis

por Donohue, James F., Kerwin, Edward, Barnes, Chris N., Moran, Edmund J., Haumann, Brett, Crater, Glenn D.
Publicado 2020

Blinded, Double‐Dummy, Parallel‐Group, Phase 2a Randomized Clinical Trial to Evaluate the Efficacy and Safety of a Highly Selective 5‐Hydroxytryptamine Type 4 Receptor Agonist in C...

por Chapman, Marianne J., Jones, Karen L., Almansa, Cristina, Barnes, Chris N., Nguyen, Deanna, Deane, Adam M.
Publicado 2020

Clinical Experience with Telavancin: Real-World Results from the Telavancin Observational Use Registry (TOUR™)

por Bressler, Adam M., Hassoun, Ali A., Saravolatz, Louis D., Ravenna, Valerie, Barnes, Chris N., Castaneda-Ruiz, Bibiana
Publicado 2019

Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease

por Donohue, James, Kerwin, Edward, Sethi, Sanjay, Haumann, Brett, Pendyala, Srikanth, Dean, Lorna, Barnes, Chris N., Moran, Edmund J., Crater, Glenn
Publicado 2019

Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)

por Donohue, James F., Kerwin, Edward, Sethi, Sanjay, Haumann, Brett, Pendyala, Srikanth, Dean, Lorna, Barnes, Chris N., Moran, Edmund J., Crater, Glenn
Publicado 2019

Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies

por Sarafoglou, Kyriakie, Barnes, Chris N, Huang, Michael, Imel, Erik A, Madu, Ivy-Joan, Merke, Deborah P, Moriarty, David, Nakhle, Samer, Newfield, Ron S, Vogiatzi, Maria G, Auchus, Richard J
Publicado 2021